Patrick Y. Wen MD
Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Director, Division of Cancer Neurology, Department of Neurology, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School, Boston, MassachusettsBiographical Sketch:
Dr. Patrick Wen is Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute and Director of the Division of Cancer Neurology in the Department of Neurology at Brigham and Women’s Hospital. He is Professor of Neurology at Harvard Medical School.
After receiving his medical degree from the Medical College of St. Bartholomew's Hospital, University of London, Dr. Wen underwent residency training at Harvard Longwood Neurology Training Program, and completed his clinical and research fellowship in neurology at the Center for Neurologic Diseases, Brigham and Women's Hospital, in Boston, Massachusetts.
Dr. Wen is a former President of the Society for Neuro-Oncology (SNO). Dr. Wen is a fellow in the Royal College of Physicians, the Royal Society of Medicine, the American Academy of Neurology, and the American Neurological Association. He is also a member of a number of other professional organizations, including the British Medical Association, American Neurological Association, Society for Neuro-Oncology, and American Society of Clinical Oncology, among others. He sits on the editorial boards of various publications, was Editor-in-Chief of Neuro-Oncology, and is currently the SNO Executive Editor.
Dr. Wen’s research focuses on novel treatments for brain tumors and optimizing response assessment and clinical trial endpoints in neuro-oncology. He is a member of the steering committee of the Response Assessment in Neuro-Oncology (RANO) Working Group. He has published and presented his research widely.
Positions:
Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute; Director, Division of Cancer Neurology, Department of Neurology, Brigham and Women’s Hospital; Professor of Neurology, Harvard Medical School, Boston, Massachusetts. Editor-in Chief, Neuro-Oncology.
Degrees:
MD: Medical College of St. Bartholomew's Hospital, University of London, England
Postgraduate Training:
Fellowship (neurology): Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, Massachusetts
Research Interests:
Novel treatments for brain tumors
Disclosures
Patrick Wen, MD, is a member of the Speaker’s Bureau for Merck and Prime Oncology.
Patrick Wen, MD, serves as a consultant/advisory board member for Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, and VBI Vaccines.
Patrick Wen, MD, received research support from Agios, Astra Zeneca, Bayer, Blue Earth Diagnostics, Immunomic Therapeutics, Karyopharm, Kiyatec, Puma, Taiho, Vascular Biogenics, Deciphera, and VBI Vaccines.
Recent Contributions to PracticeUpdate:
- IDH Inhibitors in IDH-Mutant Low-Grade and High-Grade Gliomas: A Review of Current Data
- Absence of Cytomegalovirus in Glioblastoma
- Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era
- Penetrating the Blood–Brain Barrier to Treat EGFR-Mutated NSCLC With CNS Metastases
- Targeting the PI3K Pathway for Melanoma Brain Metastases
- Checkpoint Inhibitors, Viral Therapies and Other Novel Options for Glioblastoma: An Update from SNO 2016
- New Options for Leptomeningeal Metastases: A Review from SNO 2016
- SNO 2016: Abstract Recommendations From Dr. Patrick Wen
- 2016 Top Stories in Brain Cancer: Glioma
- 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility in Patients With Glioma